

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

**(I) INSIDE INFORMATION;
(II) POSSIBLE DELAY IN PUBLICATION OF
THE 2023 ANNUAL RESULTS AND DESPATCH OF
THE 2023 ANNUAL REPORT;
(III) POSTPONEMENT OF MEETING OF THE BOARD; AND
(IV) POSSIBLE SUSPENSION OF TRADING**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a), 13.46(2) and 13.49(1) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSSIBLE DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 AND DESPATCH OF THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that there may be a delay in publication of the Company’s annual results announcement for the year ended 31 December 2023 (the “**2023 Annual Results**”) because, as at the date of this announcement, the Company is still in the process of collecting and collating the necessary information and documents from its subsidiaries as required by the auditor of the Company, HLB Hodgson Impey Cheng Limited (the “**Auditor**”) to complete the auditing process, and hence additional time is required for the Company to prepare the 2023 Annual Results. The Company is working closely with its subsidiaries and the Auditor to gather all requisite information and documents to complete the audit procedures as soon as possible. However, the expected date of the publication of the 2023 Annual Results will need to be further discussed and determined with the Auditor and will be announced as and when appropriate.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2023 Annual Results not later than three months after the end of the financial year (i.e. on or before 31 March 2024). In light of the aforementioned circumstances, it is expected that the Company is unable to publish the 2023 Annual Results on or before 31 March 2024, as required by the Listing Rules.

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2023 Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet been agreed upon with the auditors (so far as such information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2023 at this stage as they may not accurately reflect the financial performance and/or position of the Group and the publication of the unaudited management accounts could cause confusion and may be misleading to the Shareholders and potential investors of the Company.

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to despatch its annual report for the year ended 31 December 2023 (the “**2023 Annual Report**”) to the Shareholders no later than four months after the end of the financial year (i.e. on or before 30 April 2024). Due to the possible delay in the publication of the 2023 Annual Results, it is expected that there may be a possible delay in the despatch of the 2023 Annual Report. The expected date of despatch of the 2023 Annual Report will be announced as and when appropriate.

Though the delay in publication of the 2023 Annual Results and the despatch of the 2023 Annual Report would constitute non-compliance of Rules 13.49(1) and 13.46(2) of the Listing Rules, the Board wishes to emphasise that the operations of the Group remain normal, and the Company will use its best endeavours to publish the 2023 Annual Results as soon as possible. The Company expects to publish the 2023 Annual Results in the end of April 2024.

POSTPONEMENT OF BOARD MEETING

The Board announces that due to the delay in publication of the 2023 Annual Results, the meeting of the Board (the “**Board Meeting**”) for the purpose of considering and approving, among others, the 2023 Annual Results will be postponed and the Company will publish a further announcement to inform the Shareholders on the date of the relevant Board Meeting as and when appropriate.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally request suspension of trading in the issuer's securities if an issuer fails to publish periodic financial information in accordance with the Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information.

The Board will make further announcement(s) as and when appropriate to inform the Shareholders of any updates in respect of (i) the date of the Board Meeting; (ii) the publication of the 2023 Annual Results and the despatch of the 2023 Annual Report; and (iii) the possible suspension of trading in the shares of the Company.

The Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
TATA Health International Holdings Limited

Hong Kong, 25 March 2024

As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.